CANNAPHARMARX, INC.
CPMD · OTCMCIK 1081938fmd_16FZMA9Y2BKF34K0WGAR94DM7DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Cost of revenue | – | – | – | – | – | – | – | 0 | 4 | 3 |
| Realized investment gains (losses) | – | – | 0 | (7) | 0 | (7) | 0 | (0) | 0 | – |
| Gross profit | – | – | – | – | – | – | – | 0 | (3) | (2) |
| Research and development | – | – | – | – | – | – | – | – | – | – |
| Selling, general and administrative | – | – | – | – | – | – | – | 1 | 0 | – |
| Total operating expenses | 1 | 0 | 1 | 16 | 14 | 3 | 5 | 2 | 1 | 1 |
| Compensation and benefits | – | – | – | – | – | – | – | – | – | – |
| Operating income | (1) | (0) | (1) | (16) | (14) | (3) | (5) | (2) | (4) | (3) |
| Interest expense | 0 | 0 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other non-operating income (expense) | 0 | 0 | (2) | (4) | (5) | (6) | (3) | 5 | (6) | (8) |
| Income before taxes | (1) | (0) | (3) | (20) | (20) | (9) | (9) | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (1) | (0) | (3) | (20) | (20) | (9) | (9) | – | – | – |
| Net income | (1) | (0) | (3) | (20) | (20) | (9) | (9) | 4 | (10) | (11) |